Cipla Partners With China's Qilu Pharmaceutical to Bring Keytruda Biosimilar to the US

Cipla has struck a strategic partnership with China's Qilu Pharmaceutical to bring a biosimilar version of Merck's blockbuster cancer drug Keytruda to the American market, marking one of the Mumbai-headquartered drugmaker's most significant recent moves to expand its oncology portfolio in the world's largest pharmaceutical market.

Under the agreement, Cipla's wholly owned US subsidiary, Invagen Pharmaceuticals, will handle exclusive commercialization of the product, QL2107, in the United States, leveraging the company's existing US sales infrastructure and regulatory relationships. Qilu Pharmaceutical will retain responsibility for the drug's ongoing development, regulatory registration and manufacturing supply, effectively splitting the value chain between a Chinese developer with biosimilar manufacturing scale and an Indian company with established US commercial reach.

What QL2107 is

QL2107 is designed as a biosimilar to pembrolizumab, sold by Merck under the brand name Keytruda, which is among the best-selling cancer drugs in the world and is used to treat a wide range of tumors including lung, melanoma and several other solid cancers. Biosimilars are near-identical copies of complex biologic drugs that come to market once the reference product's patent protections lapse or narrow, typically at a lower price point, and are seen as a key lever for expanding patient access to expensive cancer therapies as healthcare systems grapple with rising treatment costs.

Cipla said the partnership reflects its broader strategy of building out a stronger oncology-focused portfolio in international markets, an area where the company has been steadily increasing its footprint over the past several years through both organic development and licensing deals. Achin Gupta, Cipla's Managing Director and Global Chief Executive Officer, said the tie-up underscores the company's confidence in the long-term commercial potential of biosimilars as a category, particularly as more biologic blockbusters approach the end of their exclusivity periods.

What Qilu brings to the table

Qilu Pharmaceutical, a Chinese firm with roots dating back to 1958, has built a sizeable biosimilars pipeline that includes more than 50 biosimilar candidates alongside over 130 innovative drug programs, according to the company. Hanchang Zhang, the firm's General Manager, framed the partnership as a combination of Qilu's research and manufacturing depth with Cipla's established US commercial network, positioning the joint effort to deliver what the companies describe as an affordable, high-quality alternative to the branded original.

Why this matters for Cipla investors

The deal does not involve an upfront cash outlay disclosed by either company, and QL2107 still needs to complete development milestones, secure regulatory clearance from US authorities and demonstrate it can be manufactured at commercial scale before it can reach patients — meaning any meaningful revenue contribution is likely still some years away. Even so, the announcement adds to a string of recent moves by Indian pharmaceutical majors to diversify beyond traditional small-molecule generics into more complex, higher-margin biologics and biosimilars, a segment global drugmakers increasingly view as central to future growth as patent cliffs approach for several major cancer and immunology drugs.

For Cipla, which has built its US business primarily around respiratory and generic drug categories, the Keytruda biosimilar tie-up represents another step toward establishing a credible oncology presence in a market where competition among biosimilar developers is intensifying as multiple companies race to be among the first movers once Keytruda's exclusivity narrows.

This is an original summary based on public reporting. See our editorial policy for how we source, write, and correct our stories.